The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first

The U.K. says its the very first country to authorize an oral antiviral medication to combat COVID-19. “This is necessary, since it implies it can be administered beyond a healthcare facility setting, prior to COVID-19 has actually advanced to a severe phase,” stated MHRA Chief Executive Dr. June Raine.

Justin Tallis/Pool/AFP via Getty Images

hide caption

toggle caption

Justin Tallis/Pool/AFP through Getty Images

The U.K. says its the first nation to authorize an oral antiviral medication to combat COVID-19. “This is necessary, because it means it can be administered beyond a medical facility setting, before COVID-19 has actually advanced to a severe phase,” said MHRA Chief Executive Dr. June Raine.

Justin Tallis/Pool/AFP via Getty Images

“Lagevrio is another therapeutic to include to our armory against COVID-19,” said MHRA Chief Executive Dr. June Raine. The MHRA authorized the drug for people who have moderate or moderate cases of COVID-19, along with at least one danger factor, such as weight problems, heart illness or being 60 or older. COVID-19 rates are currently high in the U.K. with 1.1 million cases over the past 28 days– the second-most cases in the world (after the U.S.), according to Johns Hopkins University.

Mercks antiviral tablet that battles COVID-19 in adults with the illness won its very first permission in the world Thursday, as the U.K.s medical regulator announced that the drug is “efficient and safe at reducing the danger of hospitalization and death” in moderate to moderate cases. “Today is a historic day for our nation, as the U.K. is now the very first country in the world to authorize an antiviral that can be taken at house for COVID-19,” Javid stated. The U.K.s permission is based on medical research studies that revealed the drug minimized the risk of hospitalization or death by about 50% for at-risk adults with moderate to moderate COVID-19 cases.

Mercks antiviral pill that fights COVID-19 in grownups with the disease won its first authorization in the world Thursday, as the U.K.s medical regulator revealed that the drug is “efficient and safe at reducing the danger of hospitalization and death” in mild to moderate cases. “Today is a historic day for our country, as the U.K. is now the very first country in the world to authorize an antiviral that can be taken at home for COVID-19,” Javid said. The U.K.s authorization is based on medical studies that showed the drug minimized the risk of hospitalization or death by about 50% for at-risk grownups with moderate to moderate COVID-19 cases.”Lagevrio is another restorative to include to our armory against COVID-19,” said MHRA Chief Executive Dr. June Raine.

Leave a Reply

Your email address will not be published. Required fields are marked *